GlassScriptPhysician profile
Steven M Alexander
NPI 1891873618
$2,083.79
in general payments reported to CMS, 2019-2025
25 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $185 · 2022: $345 · 2023: $729 · 2024: $358 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $799.70 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $284.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $149.67 | 2022 | |
| Pfizer INC. | $148.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $100.31 | 2024-2025 | Airsupra, Breztri |
| Corcept Therapeutics | $86.13 | 2023-2025 | Korlym |
| Myriad Women'S Health, INC. | $85.48 | 2023 | Myrisk |
| Phathom Pharmaceuticals, INC. | $51.43 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $42.02 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.60 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.22 | 2023 | Jardiance |
| Azurity Pharmaceuticals, INC. | $28.30 | 2023-2024 | Edarbi, Edarbi |
| Philips North America LLC | $27.17 | 2021-2023 | |
| Alkermes, INC. | $25.66 | 2025 | Vivitrol |
| Abbott Laboratories | $24.58 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $20.70 | 2024 | |
| Tactile Systems Technology INC | $20.27 | 2023 | Flexitouch Plus, Entre Plus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.11 | 2025 | Xifaxan |
| Amgen INC. | $17.63 | 2022 | |
| Abbvie INC. | $16.01 | 2023 | Vraylar |
| Amarin Pharma, INC. | $15.96 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.25 | 2024 | |
| Dexcom, INC. | $13.43 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $13.18 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.